Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early-stage follicular lymphoma radiotherapy plus anti-CD20 antibody trial
2023-509278-41-00Phase 3Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing MabThera plus radiotherapy with Gazyvaro plus radiotherapy (2 arms). Primary endpoint: Morphologic complete response at week 18. Planned start Jul 2022; status: authorised.
02
Drugs
rituximabobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-509278-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509278-41-00.